Back to Journals » Open Access Rheumatology: Research and Reviews » Volume 6

Serum anticyclic citrullinated protein antibody titers are correlated with the response to biological agents in patients with rheumatoid arthritis

Authors Takahashi R, Isojima S, Umemura M, Miura Y, Oguro N, Ishii S, Seki S, Tokunaga T, Tsukamoto H, Furuya H, Yanai R, Kasama T

Received 5 December 2013

Accepted for publication 3 February 2014

Published 16 May 2014 Volume 2014:6 Pages 57—64

DOI https://doi.org/10.2147/OARRR.S58772

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3


Ryo Takahashi, Sakiko Isojima, Masayu Umemura, Yoko Miura, Nao Oguro, Syo Ishii, Shinya Seki, Takahiro Tokunaga, Hiroyuki Tsukamoto, Hidekazu Furuya, Ryo Yanai, Tsuyoshi Kasama
Division of Rheumatology, Department of Medicine, Showa University School of Medicine,
Tokyo, Japan 
Abstract: Anticyclic citrullinated protein antibody (ACPA) is known as an important indicator for diagnosis of rheumatoid arthritis (RA). Our aim was to examine the relationship between the serum ACPA titer at baseline and responsiveness to biological agents (antagonists of either tumor necrosis factor or interleukin 6) in patients with RA. ACPA was measured using second-generation chemiluminescent enzyme immunoassay. Disease activity was assessed using disease activity scores 28. Fifty-seven RA patients with biological agents were enrolled, and the median ACPA titer at baseline was 110.0 U/mL. The median ACPA titer was 23.3 U/mL and 183.0 U/mL in the good and moderate response groups, respectively, which were significantly lower than in the no response group (404.0 U/mL). In addition, 69.2% and 26.9% of patients with low (<100 U/mL) and moderate (100–499 U/mL) basal ACPA titers showed a moderate to good response. Of the patients with higher (≥500 U/mL) basal ACPA titers, only 14.0% and 42.5% showed a good or moderate response, respectively. The remission rate was 77.8% in the ACPA-negative, which was significantly higher than the rate of 25% in the ACPA-positive patients. The results suggest that the ACPA titers are correlated with the efficacy of the biological agents used in patients with RA.


Keywords: biological agents, remission

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]